ATTR-CM sykdomsmekanisme¹

1. Castano A, Narotsky D, Maurer MS, et al. Emerging therapies for transthyretin cardiac amyloidosis could herald a new era for the treatment of HFPEF. J Am Coll Cardiol. 2015. https:///www.acc.org/latest-in-cardiology/articles/2015/10/13/08/35/emerging-therapies-for-transthyretin-cardiac-amyloidosis Accessed January 4, 2019
2. Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109(24):9629-9634.

SPC
Felleskatalogtekst